Compare · BIS vs DWUS
BIS vs DWUS
Side-by-side comparison of ProShares UltraShort Nasdaq Biotechnology (BIS) and AdvisorShares Dorsey Wright FSM US Core ETF (DWUS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BIS and DWUS operate in n/a (n/a), so they compete in similar markets.
- Over the past year, BIS is down 48.2% and DWUS is up 6.6% - DWUS leads by 54.8 points.
ProShares UltraShort Nasdaq Biotechnology
The investment seeks daily investment results that correspond to two times the inverse (-2x) of the daily performance of the Nasdaq Biotechnology Index®. The fund invests in financial instruments that ProShare Advisors believes, in combination, should produce daily returns consistent with the fund's investment objective. The index is a modified capitalization weighted index that includes securities of Nasdaq listed companies that are classified as either biotechnology or pharmaceutical. The fund is non-diversified.
AdvisorShares Dorsey Wright FSM US Core ETF
The investment seeks to provide long-term capital appreciation with capital preservation as a secondary objective. The fund is an actively managed exchange-traded fund ("ETF") that is primarily a "fund of funds." The Advisor seeks to achieve it's investment objective by investing in ETFs that invest primarily in domestic large capitalization equity securities. The fund invests in fixed income ETFs with a short or ultra-short duration, money market funds, cash and cash equivalents ("Defensive Investments"). It may invest in affiliated and unaffiliated ETFs. Under normal circumstances, the fund invests at least 80% of its net assets in U.S. investments.